Drug Trial Radar · NCT00979745
Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)
Last checked: Nov 20, 2026Latest source record: Oct 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Sep 2009
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- Clinuvel Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Afamelanotide is a man-made drug being studied for use as a preventative medication for EPP sufferers. It is a synthetically produced analogue of human alpha melanocyte stimulating hormone (alpha-MSH) and is not yet available on the market. The purpose of this study is to look at whether afamelanotide can reduce the number and severity of EPP symptoms when patients are exposed to light. This study will also look at how the drug is tolerated when taken by people with EPP. The study will involve the use of an implant, which comes in the form of a small rod (approximately 2 cm x 0.15 cm) to be administered under the skin. The implant may contain the study drug afamelanotide or a placebo (inactive medication). Over 450 subjects have been treated with afamelanotide to date with no serious safety concerns identified. For this study, afamelanotide has been formulated as a controlled release depot injection (implant). This means that the afamelanotide will be released slowly into the body over a few days. Once inserted, the implant will remain in the body after afamelanotide has been released and will slowly dissolve. This study will help to provide more information about afamelanotide. This information will be used to determine the safety and efficacy (the ability of the drug to produce an effect) of this drug in EPP sufferers. Up to 70 people will participate in this study from study sites across Europe.
Conditions
- Erythropoietic Protoporphyria
Interventions
AfamelanotideDrug
One 16mg subcutaneous implant every 2 months for 9 months.
PlaceboDrug
One 16mg subcutaneous implant every 2 months for 9 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Duration of Direct Sunlight Exposure Between 10:00 and 15:00 Hours on Days When Patients Did Not Report Phototoxicity-related Pain (Likert Pain Scale Score of 0)Time frame: From baseline to Day 270
Locations
8 sites in 6 countries. Site status is shown where the registry gives one.
HUS:n Iho-ja allergiasairaala (Skin and Allergy Hospital)
Helsinki, Finland
Centre Français des Porphyries, Hôpital Louis Mourier
Colombes, Cedex, France
Department of Dermatology , Heinrich-Heine-University Duesseldorf
Düsseldorf, Germany
Beaumont Hospital, Department of Dermatology
Dublin, Ireland
Academisch Ziekenhuis Maastricht
Maastricht, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
Photobiology Unit - Hope Hospital, University of Manchester
Manchester, United Kingdom
St Woolos Hospital
Newport, Wales, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.